Kidney transplantation and enzyme replacement therapy in patients with Fabry disease

Journal of Nephrology

Volumn 26, Issue 4, 2013, Pages 645-651

  Cybulla, Markus ^a   Kurschat, Christine ^b   West, Michael ^c   Nicholls, Kathy ^d   Torras, Joan ^e   Sunder Plassmann, Gere ^f   Feriozzi, Sandro ^g  

^a Department of Nephrology and Rheumatology   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c DALHOUSIE UNIVERSITY   (Canada)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e UNIVERSITY OF BARCELONA   (Spain)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g BELCOLLE HOSPITAL   (Italy)

Author keywords

Agalsidase alfa; Agalsidase beta; End stage renal disease (ESRD); Enzyme replacement therapy (ERT); Fabry disease; Kidney transplantation; Nephropathy

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALPHA GALACTOSIDASE; CREATININE; GLOBOTRIAOSYLCERAMIDE; GLYCOSPHINGOLIPID; IMMUNOSUPPRESSIVE AGENT;

CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FABRY DISEASE; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PROGNOSIS; PROTEINURIA; RENAL REPLACEMENT THERAPY; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UREMIA;

ALPHA-GALACTOSIDASE; DISEASE PROGRESSION; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; HUMANS; ISOENZYMES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION;

EID: 84880089118     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000214     Document Type: Review

References (40)

1. Pastores GM, Thadhani R. Advances in the management of Anderson-Fabry disease: enzyme replacement therapy. Expert Opin Biol Ther. 2002;2(3):325-333.
2. Cybulla M, Schaefer E, Wendt S, et al. Chronic renal failure and proteinuria in adulthood: Fabry disease predominantly affecting the kidneys. Am J Kidney Dis. 2005;45(5): e82-e89.
3. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001; 38(11):769-775.
4. MacDermot KD, Holmes A, Miners AH. Natural history of Fabry disease in affected males and obligate carrier females. J Inherit Metab Dis. 2001; 24 2 (Suppl 2):13-14 discussion 11-12.
5. Fabry J. Ein Beitrag zur Kenntnis der Purpura haemorrhagica nodularis (Purpura papulosa hemorrhagica Hebrae). Arch Derm Syphilol. 1898;43:187-200.
6. Anderson W. A case of "angio-keratoma". Br J Dermatol. 1898;10(4):113-117.
7. Grünfeld JP, Chauveau D, Lévy M. Anderson-Fabry disease: its place among other genetic causes of renal disease. J Am Soc Nephrol. 2002;13(Suppl 2):S126-S129.
8. Gubler MC, Lenoir G, Grünfeld JP, et al. Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int. 1978;13(3):223-235.
9. Branton M, Schiffmann R, Kopp JB. Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol. 2002;13(Suppl 2):S139-S143.
10. Feriozzi S, Schwarting A, Sunder-Plassmann G, West M, Cybulla M; International Fabry Outcome Survey Investigators. Agalsidase alfa slows the decline in renal function in patients with Fabry disease. Am J Nephrol. 2009;29(5):353-361.
11. Sessa A, Meroni M, Battini G, et al. Renal pathological changes in Fabry disease. J Inherit Metab Dis. 2001;24 2 Suppl 2:66-70, discussion 65.
12. Thurberg BL, Rennke H, Colvin RB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. 2002;62(6):1933-1946.
13. Tøndel C, Bostad L, Hirth A, Svarstad E. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis. 2008;51(5):767-776.
14. Valbuena C, Carvalho E, Bustorff M, et al. Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy. Virchows Arch. 2008;453(4):329-338.
15. Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore). 2002;81(2):122-138.
16. Alroy J, Sabnis S, Kopp JB. Renal pathology in Fabry disease. J Am Soc Nephrol. 2002;13(Suppl 2):S134-S138.
17. Fogo AB, Bostad L, Svarstad E, et al. All members of the International Study Group of Fabry Nephropathy (ISGFN). Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant. 2010;25(7):2168-2177.
18. Najafian B, Svarstad E, Bostad L, et al. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int. 2011; 79(6):663-670.
19. Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009;24(7):2102-2111.
20. Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C; Fabry Registry. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant. 2008;23(5):1600-1607.
21. Shah T, Gill J, Malhotra N, Takemoto SK, Bunnapradist S. Kidney transplant outcomes in patients with Fabry disease. Transplantation. 2009;87(2):280-285.
22. Ojo A, Meier-Kriesche HU, Friedman G, et al. Excellent outcome of renal transplantation in patients with Fabry's disease. Transplantation. 2000;69(11):2337-2339.
23. Tsakiris D, Simpson HK, Jones EH, et al. Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant. 1996;11(Suppl 7):4-20.
24. Nissenson AR, Port FK. Outcome of end-stage renal disease in patients with rare causes of renal failure. I. Inherited and metabolic disorders. Q J Med. 1989;73(271):1055-1062.
25. Groth CG, Ringdén O. Transplantation in relation to the treatment of inherited disease. Transplantation. 1984;38(4): 319-327.
26. Ramos EL, Tisher CC. Recurrent diseases in the kidney transplant. Am J Kidney Dis. 1994;24(1):142-154.
27. Gantenbein H, Bruder E, Burger HR, Briner J, Binswanger U. Recurrence of Fabry's disease in a renal allograft 14 years after transplantation. Nephrol Dial Transplant. 1995;10(2): 287-289.
28. Grünfeld JP, Le Porrier M, Droz D, Bensaude I, Hinglais N, Crosnier J. [Renal transplantation in patients suffering from Fabry's disease. Kidney transplantation from an heterozygote subject to a subject without Fabry's disease]. Nouv Presse Med. 1975;4(29):2081-2085.
29. Popli S, Molnar ZV, Leehey DJ, et al. Involvement of renal allograft by Fabry's disease. Am J Nephrol. 1987;7(4):316-318.
30. Puliyanda DP, Wilcox WR, Bunnapradist S, Nast CC, Jordan SC. Fabry disease in a renal allograft. Am J Transplant. 2003;3(8):1030-1032.
31. Basic-Jukic N, Coric M, Kes P, Bubic-Filipi LJ, Pasini J, Mokos I. Anderson-Fabry disease in kidneys from deceased donor. Am J Transplant. 2007;7(12):2829-2833.
32. Kleinert J, Kotanko P, Spada M, et al. Anderson-Fabry disease: a case-finding study among male kidney transplant recipients in Austria. Transpl Int. 2009;22(3):287-292.
33. Inderbitzin D, Avital I, Largiadèr F, Vogt B, Candinas D. Kidney transplantation improves survival and is indicated in Fabry's disease. Transplant Proc. 2005;37(10):4211-4214.
34. Barbey F, Lidove O, Schwarting A. Fabry nephropathy: 5 years of enzyme replacement therapy-a short review. NDT Plus. 2008;1(1):11-19.
35. Mignani R, Feriozzi S, Schaefer RM, et al. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy. Clin J Am Soc Nephrol. 2010;5(2):379-385.
36. West M, Nicholls K, Mehta A, et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol. 2009; 20(5):1132-1139.
37. Mignani R, Panichi V, Giudicissi A, et al. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study. Kidney Int. 2004;65(4): 1381-1385.
38. Pastores GM, Boyd E, Crandall K, Whelan A, Piersall L, Barnett N. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease. Nephrol Dial Transplant. 2007;22(7):1920-1925.
39. Mignani R, Feriozzi S, Pisani A, et al. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy. Nephrol Dial Transplant. 2008; 23(5):1628-1635.
40. Cybulla M, Walter KN, Schwarting A, Divito R, Feriozzi S, Sunder-Plassmann G; European FOS Investigators Group. Kidney transplantation in patients with Fabry disease. Transpl Int. 2009;22(4):475-481.